The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes

Lenalidomide and dexamethasone (LEN plus DEX) treatment in relapsed/refractory multiple myeloma (RRMM) patients (pts) and risk of second primary malignancies (SPM): Analysis of MM-009/010.

(2017) M. A. Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence of second primary malignancy (SPM) in melphalan-prednisone-lenalidomide combination followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma patients (pts) age 65 or older.

(2017) A. P. Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605

(2011) M. A. Sekeres et al.   BLOOD

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

(2011) P. Fenaux et al.   BLOOD

The relative risk of second primary cancers in Queensland, Australia: a retrospective cohort study

(2011) Danny R Youlden et al.   BMC CANCER

Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

(2011) M A Dimopoulos et al.   LEUKEMIA

Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes

(2010) Mikkael A. Sekeres et al.   AMERICAN JOURNAL OF HEMATOLOGY

Balancing act for elderly myeloma

(2010) A. Palumbo   BLOOD

Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)

(2010) J. A. Zonder et al.   BLOOD

Lenalidomide mode of action: linking bench and clinical findings

(2010) Faith Davies et al.   BLOOD REVIEWS

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

(2010) Meletios Dimopoulos et al.   CANCER

Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone

(2010) Jesús F. San-Miguel et al.   Clinical Lymphoma Myeloma & Leukemia

Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function

(2010) A. K. Gandhi et al.   CURRENT CANCER DRUG TARGETS

Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion

(2010) Esther N. Oliva et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Meeting the Unmet Needs in Anticoagulant Therapy

(2010)   EUROPEAN JOURNAL OF HAEMATOLOGY

Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study

(2010) Javier De La Rubia et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Managing the teratogenic risk of thalidomide and lenalidomide: an industry perspective

(2010) Robert Bwire et al.   Expert Opinion On Drug Safety

Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes

(2010) Carla Heise et al.   Expert Review of Anticancer Therapy

Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma

(2010) J.-L. Harousseau et al.   HAEMATOLOGICA

Abnormal modulation of cell protective systems in response to ischemic/reperfusion injury is important in the development of mouse sickle cell hepatopathy

(2010) A. Siciliano et al.   HAEMATOLOGICA

Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes

(2010) Mikkael A. Sekeres et al.   JOURNAL OF CLINICAL ONCOLOGY

Second Malignancy Risks After Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: Differences by Lymphoma Subtype

(2010) Lindsay M. Morton et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients

(2010) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Persistent Malignant Stem Cells in del(5q) Myelodysplasia in Remission

(2010) Ramin Tehranchi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression

(2009) Gudrun Göhring et al.   ANNALS OF HEMATOLOGY

Risky business in myeloma

(2009) S. Lonial   BLOOD

Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy

(2009) A. G. Ramsay et al.   BLOOD

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

(2009) P. Richardson et al.   BLOOD

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells

(2009) M Lioznov et al.   BONE MARROW TRANSPLANTATION

Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism

(2009) L. Escoubet-Lozach et al.   CANCER RESEARCH

Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion

(2009) M. Ximeri et al.   HAEMATOLOGICA

Survival Effect of Venous Thromboembolism in Patients With Multiple Myeloma Treated With Lenalidomide and High-Dose Dexamethasone

(2009) Maurizio Zangari et al.   JOURNAL OF CLINICAL ONCOLOGY

Mechanism of action of lenalidomide in hematological malignancies

(2009) Venumadhav Kotla et al.   Journal of Hematology & Oncology

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

(2009) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

(2009) M A Dimopoulos et al.   LEUKEMIA

5q– myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics

(2009) K M Eisenmann et al.   ONCOGENE

Integrated Genomic Analysis Implicates Haploinsufficiency of Multiple Chromosome 5q31.2 Genes in De Novo Myelodysplastic Syndromes Pathogenesis

(2009) Timothy A. Graubert et al.   PLoS One

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

(2009) S. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes

(2008) Aristoteles Giagounidis et al.   ANNALS OF HEMATOLOGY

Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone

(2008) Ulrike Klein et al.   ANNALS OF HEMATOLOGY

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study

(2008) L. Ades et al.   BLOOD

Thalidomide for treatment of multiple myeloma: 10 years later

(2008) A. Palumbo et al.   BLOOD

Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells

(2008) L. Wu et al.   CLINICAL CANCER RESEARCH

Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes

(2008) Mikkael A. Sekeres et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide

(2008) C. Kelaidi et al.   LEUKEMIA RESEARCH

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

(2008) Benjamin L. Ebert et al.   NATURE

An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome

(2008) Benjamin L Ebert et al.   PLOS MEDICINE